Because CBFB is already sequenced on major cancer gene panels in clinical use, no additional testing infrastructure is required: CBFB mutation status is a low-cost candidate for prospective validation in endocrine-therapy studies, and, if confirmed, could be reported alongside existing panel results to inform treatment decisions. This evidence concerns the gene CBFB and cancer.